- STAT+: Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drugAhead of a hearing, the FDA raised questions about the benefits of a Duchenne treatment from Capricor Therapeutics, another twist for the rare disease drug.
- A trend that isn’t fading, ultra-processed baby foodsAn FDA advisory panel serves some peptide wins, a measles record, and more health news from Morning Rounds